ABBV
$285.42+0.71%
as of close, Oct 16, 2026
☾ AH $285.42 +0.71%
ABBV SEC filings (2026)
CIK 1551152 · Pharmaceutical Preparations (SIC 2834) · incorporated in DE · fiscal year ends in December
1,514 filings on EDGAR since 2012 · 15 annual, 41 quarterly, 202 current · financial statements · earnings
Latest 10-K
Feb 20, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Aug 3, 2026
quarter to Jun 30, 2026
Latest 8-K
Oct 15, 2026
Directors or officers; compensation
Last earnings release
Oct 5, 2026
8-K, Item 2.02
Filings on file
1,514
since 2012, 916 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
October 2026
- Oct 158-K8-K · Directors or officers; compensation
- Oct 58-K8-K · Results of operations
September 2026
- Sep 38-K8-K · AbbVie Completes Acquisition of Apogee TherapeuticsRegulation FD disclosure
August 2026
- Aug 188-K8-K · Other events
- Aug 14Insider saleDonoghoe Nicholas (EVP, CHIEF BUS/STRAT OFFICER) sold 32,710 shares for $8.2M at $250.00
- Aug 58-K8-K · Other events
- Aug 3ReportQuarterly report, Q2 2026 — revenue $16.99B (+10% y/y), net income $3.61B, EPS $2.03
July 2026
- Jul 31EarningsEarnings release — EPS $3.65 vs $3.64 est. (+0.3%); revenue $16.99B (+10% y/y) 2.5%
- Jul 68-K8-K · Results of operations
June 2026
- Jun 228-K8-K · AbbVie to Acquire Apogee Therapeutics, Deepening Immunology PortfolioRegulation FD disclosure
May 2026
April 2026
- Apr 29EarningsEarnings release — EPS $2.65 vs $2.62 est. (+1.1%); revenue $15.00B (+12% y/y) 3.1%
- Apr 38-K8-K · Results of operations
March 2026
- Mar 23ProxyProxy · Annual report to shareholders
- Mar 23ProxyProxy · Additional proxy materials
- Mar 23ProxyProxy · Proxy statement
- Mar 9ProxyProxy · Preliminary proxy statement
- Mar 4Insider salePurdue David Ryan (SVP, Controller) sold 5,230 shares for $1.2M at $233.56
- Mar 48-K8-K · Other events
- Mar 2Insider saleSiatis Perry C (EVP, GC AND SECRETARY) sold 18,668 shares for $4.4M at $233.51–$235.26 under a 10b5-1 plan
February 2026
- Feb 268-K8-K · Other events
- Feb 25Insider saleSiatis Perry C (EVP, GC AND SECRETARY) sold 22,381 shares for $5.1M at $230.00 under a 10b5-1 plan
- Feb 20ReportAnnual report, FY2025 — revenue $61.16B (+9% y/y), net income $4.23B, EPS $2.36
- Feb 4EarningsEarnings release — EPS $2.71 vs $2.66 est. (+1.9%); revenue $16.62B (+10% y/y) 3.8%
January 2026
- Jan 78-K8-K · Results of operations
November 2025
October 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $18.9M in 4 sales and bought nothing on the open market; 52 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Aug 14, 2026Form 4 | Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERSold · $8.2M · 32,710 sh |
| Mar 4, 2026Form 4 | Purdue David RyanSVP, ControllerSold · $1.2M · 5,230 sh |
| Mar 2, 2026Form 4 | Siatis Perry CEVP, GC AND SECRETARYSold · $4.4M · 18,668 sh · 10b5-1 |
| Feb 25, 2026Form 4 | Siatis Perry CEVP, GC AND SECRETARYSold · $5.1M · 22,381 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 52 transactions
| Date | Insider |
|---|---|
| Sep 30, 2026Form 4 | RAPP EDWARD JDirectorAward · Stock Equivalent Units · $34K · 129 sh |
| Sep 30, 2026Form 4 | Quaggin Susan EDirectorAward · Stock Equivalent Units · $15K · 59 sh |
| Aug 14, 2026Form 4 | Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERExercise or conversion · $2.6M · 32,710 sh |
| Aug 14, 2026Form 4 | Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERExercise or conversion · Option (Right to buy) · $0 · 32,710 sh |
| Jun 30, 2026Form 4 | RAPP EDWARD JDirectorAward · Stock Equivalent Units · $34K · 134 sh |
| Jun 30, 2026Form 4 | Quaggin Susan EDirectorAward · Stock Equivalent Units · $16K · 62 sh |
| May 8, 2026Form 4 | AUSTIN ROXANNE SDirectorAward · $0 · 1,118 sh |
| May 8, 2026Form 4 | RAPP EDWARD JDirectorAward · $0 · 1,118 sh |
| May 8, 2026Form 4 | FALK THOMAS JDirectorAward · $0 · 1,118 sh |
| May 8, 2026Form 4 | WADDELL FREDERICK HDirectorAward · $0 · 1,118 sh |
| May 8, 2026Form 4 | FREYMAN THOMAS CDirectorAward · $0 · 1,118 sh |
| May 8, 2026Form 4 | Roberts Rebecca BDirectorAward · $0 · 1,118 sh |
| May 8, 2026Form 4 | Hart Brett JDirectorAward · $0 · 1,118 sh |
| May 8, 2026Form 4 | BURNSIDE WILLIAM H.L.DirectorAward · $0 · 1,118 sh |
| May 8, 2026Form 4 | MEYER MELODY BDirectorAward · $0 · 1,118 sh |
| May 8, 2026Form 4 | Davis Jennifer L.DirectorAward · $0 · 1,118 sh |
| May 8, 2026Form 4 | Quaggin Susan EDirectorAward · $0 · 1,118 sh |
| Mar 31, 2026Form 4 | RAPP EDWARD JDirectorAward · Stock Equivalent Units · $34K · 155 sh |
| Mar 31, 2026Form 4 | Quaggin Susan EDirectorAward · Stock Equivalent Units · $15K · 71 sh |
| Mar 31, 2026Form 4 | Alpern Robert JDirectorAward · Stock Equivalent Units · $7,612 · 35 sh |
| Feb 27, 2026Form 4 | Michael Robert A.CHAIRMAN OF THE BOARD AND CEO · DirectorTax withholding · $8.5M · 36,523 sh |
| Feb 27, 2026Form 4 | Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERTax withholding · $5.5M · 23,812 sh |
| Feb 27, 2026Form 4 | Reents Scott TEVP, CHIEF FINANCIAL OFFICERTax withholding · $5.0M · 21,638 sh |
| Feb 27, 2026Form 4 | SALEKI-GERHARDT AZITAEVP, CHIEF OPERATIONS OFFICERTax withholding · $3.8M · 16,309 sh |
| Feb 27, 2026Form 4 | Siatis Perry CEVP, GC AND SECRETARYTax withholding · $3.4M · 14,850 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERTax withholding · $3.0M · 12,874 sh |
| Feb 27, 2026Form 4 | Thakkar RoopalEVP, R&D and CSOTax withholding · $1.9M · 8,037 sh |
| Feb 27, 2026Form 4 ×2 | Purdue David RyanSVP, ControllerTax withholding · $1.1M · 4,800 sh |
| Feb 27, 2026Form 4 | Crum Demetris DEVP, CHIEF HR OFFICERTax withholding · $370K · 1,594 sh |
| Feb 25, 2026Form 4 | Siatis Perry CEVP, GC AND SECRETARYExercise or conversion · $3.9M · 22,381 sh · 10b5-1 |
| Feb 25, 2026Form 4 | Siatis Perry CEVP, GC AND SECRETARYExercise or conversion · Option (Right to buy) · $3.9M · 22,381 sh · 10b5-1 |
| Feb 18, 2026Form 4 | Michael Robert A.CHIEF EXECUTIVE OFFICER · DirectorAward · $0 · 82,439 sh |
| Feb 18, 2026Form 4 | Michael Robert A.CHIEF EXECUTIVE OFFICER · DirectorAward · Option (Right to Buy) · $0 · 81,251 sh |
| Feb 18, 2026Form 4 | Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERAward · $0 · 53,749 sh |
| Feb 18, 2026Form 4 | Reents Scott TEVP, CHIEF FINANCIAL OFFICERAward · $0 · 48,838 sh |
| Feb 18, 2026Form 4 | SALEKI-GERHARDT AZITAEVP, CHIEF OPERATIONS OFFICERAward · $0 · 36,811 sh |
| Feb 18, 2026Form 4 | Siatis Perry CEVP, GC AND SECRETARYAward · $0 · 33,518 sh |
| Feb 18, 2026Form 4 | Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERAward · $0 · 29,057 sh |
| Feb 18, 2026Form 4 | Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICERAward · Option (Right to Buy) · $0 · 26,812 sh |
| Feb 18, 2026Form 4 | Reents Scott TEVP, CHIEF FINANCIAL OFFICERAward · Option (Right to buy) · $0 · 21,937 sh |
| Feb 18, 2026Form 4 | Thakkar RoopalEVP, R&D and CSOAward · Option (Right to buy) · $0 · 21,937 sh |
| Feb 18, 2026Form 4 | SALEKI-GERHARDT AZITAEVP, CHIEF OPERATIONS OFFICERAward · Option (Right to Buy) · $0 · 20,312 sh |
| Feb 18, 2026Form 4 | Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICERAward · Option (Right to buy) · $0 · 20,312 sh |
| Feb 18, 2026Form 4 | Siatis Perry CEVP, GC AND SECRETARYAward · Option (Right to buy) · $0 · 19,500 sh |
| Feb 18, 2026Form 4 | Thakkar RoopalEVP, R&D and CSOAward · $0 · 18,137 sh |
| Feb 18, 2026Form 4 | Crum Demetris DEVP, CHIEF HR OFFICERAward · Option (Right to buy) · $0 · 13,406 sh |
| Feb 18, 2026Form 4 | Purdue David RyanSVP, ControllerAward · $0 · 6,071 sh |
| Feb 18, 2026Form 4 | Purdue David RyanSVP, ControllerAward · Option (Right to buy) · $0 · 4,875 sh |
| Feb 18, 2026Form 4 | Crum Demetris DEVP, CHIEF HR OFFICERAward · $0 · 2,460 sh |
| Dec 31, 2025Form 4 | RAPP EDWARD JDirectorAward · Stock Equivalent Units · $34K · 147 sh |
| Dec 31, 2025Form 4 | Quaggin Susan EDirectorAward · Stock Equivalent Units · $16K · 68 sh |
| Dec 31, 2025Form 4 | Alpern Robert JDirectorAward · Stock Equivalent Units · $7,769 · 34 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 22 filings
| Filed | What it is |
|---|---|
| Oct 15, 20268-K | Directors or officers; compensation |
| Oct 5, 20268-K | Results of operations |
| Sep 3, 20268-K | AbbVie Completes Acquisition of Apogee TherapeuticsRegulation FD disclosure |
| Aug 18, 20268-K | Other events |
| Aug 5, 20268-K | Other events |
| Aug 3, 202610-Q | Quarterly report, Q2 2026 — revenue $16.99B (+10% y/y), net income $3.61B, EPS $2.03 |
| Jul 31, 20268-K | Earnings release — EPS $3.65 vs $3.64 est. (+0.3%); revenue $16.99B (+10% y/y) 2.5% |
| Jul 6, 20268-K | Results of operations |
| Jun 22, 20268-K | AbbVie to Acquire Apogee Therapeutics, Deepening Immunology PortfolioRegulation FD disclosure |
| May 12, 20268-K | Shareholder vote results |
| May 8, 202610-Q | Quarterly report, Q1 2026 — revenue $15.00B (+12% y/y), net income $695.0M, EPS $0.39 |
| Apr 29, 20268-K | Earnings release — EPS $2.65 vs $2.62 est. (+1.1%); revenue $15.00B (+12% y/y) 3.1% |
| Apr 3, 20268-K | Results of operations |
| Mar 23, 2026ARS | Annual report to shareholders |
| Mar 23, 2026DEFA14A | Additional proxy materials |
| Mar 23, 2026DEF 14A | Proxy statement |
| Mar 9, 2026PRE 14A | Preliminary proxy statement |
| Mar 4, 20268-K | Other events |
| Feb 26, 20268-K | Other events |
| Feb 20, 202610-K | Annual report, FY2025 — revenue $61.16B (+9% y/y), net income $4.23B, EPS $2.36 |
| Feb 4, 20268-K | Earnings release — EPS $2.71 vs $2.66 est. (+1.9%); revenue $16.62B (+10% y/y) 3.8% |
| Jan 7, 20268-K | Results of operations |
2025 · 23 filings
| Filed | What it is |
|---|---|
| Nov 4, 202510-Q | Quarterly report, Q3 2025 — revenue $15.78B (+9% y/y), net income $186.0M, EPS $0.10 |
| Oct 31, 20258-K | Earnings release — EPS $1.86 vs $1.77 est. (+5.1%); revenue $15.78B (+9% y/y) 4.5% |
| Oct 3, 20258-K | Results of operations |
| Sep 11, 20258-K | Regulation FD disclosure |
| Aug 4, 202510-Q | Quarterly report, Q2 2025 — revenue $15.42B (+7% y/y), net income $938.0M, EPS $0.52 |
| Jul 31, 20258-K | Results of operations |
| Jul 3, 20258-K | Results of operations |
| May 13, 20258-K | Directors or officers; compensation; Shareholder vote results |
| May 9, 202510-Q | Quarterly report, Q1 2025 — revenue $13.34B (+8% y/y), net income $1.29B, EPS $0.72 |
| Apr 25, 20258-K | Results of operations |
| Apr 3, 20258-K | Results of operations |
| Mar 25, 2025ARS | Annual report to shareholders |
| Mar 24, 2025DEFA14A | Additional proxy materials |
| Mar 24, 2025DEF 14A | Proxy statement |
| Mar 10, 2025PRE 14A | Preliminary proxy statement |
| Feb 26, 20258-K | Other events |
| Feb 19, 20258-K | Other events |
| Feb 14, 202510-K | Annual report, FY2024 — revenue $56.33B (+4% y/y), net income $4.28B, EPS $2.39 |
| Feb 14, 20258-K | Directors or officers; compensation; Regulation FD disclosure |
| Feb 5, 20258-K | Other events |
| Jan 31, 20258-K | Results of operations |
| Jan 10, 20258-K | Material impairment |
| Jan 6, 20258-K | Results of operations |
2024 · 24 filings
| Filed | What it is |
|---|---|
| Dec 13, 20248-K | Directors or officers; compensation |
| Nov 4, 202410-Q | Quarterly report, Q3 2024 — revenue $14.46B (+4% y/y), net income $1.56B, EPS $0.88 |
| Oct 30, 20248-K | Results of operations |
| Oct 3, 20248-K | Results of operations |
| Sep 10, 20248-K | Charter, bylaws or fiscal-year change |
| Aug 7, 202410-Q | Quarterly report, Q2 2024 — revenue $14.46B (+4% y/y), net income $1.37B, EPS $0.77 |
| Jul 25, 20248-K | Results of operations |
| Jul 3, 20248-K | Results of operations |
| May 8, 20248-K/A | Directors or officers; compensation; Shareholder vote results |
| May 3, 202410-Q | Quarterly report, Q1 2024 — revenue $12.31B (+1% y/y), net income $1.37B, EPS $0.77 |
| Apr 26, 20248-K | Results of operations |
| Apr 3, 20248-K | Results of operations |
| Apr 2, 2024PX14A6G | Shareholder exempt solicitation |
| Mar 26, 2024PX14A6G | Shareholder exempt solicitation |
| Mar 18, 2024ARS | Annual report to shareholders |
| Mar 18, 2024DEFA14A | Additional proxy materials |
| Mar 18, 2024DEF 14A | Proxy statement |
| Mar 4, 2024PRE 14A | Preliminary proxy statement |
| Feb 26, 20248-K | Other events |
| Feb 20, 202410-K | Annual report, FY2023 — revenue $54.32B (−6% y/y), net income $4.86B, EPS $2.72 |
| Feb 20, 20248-K | Directors or officers; compensation; Regulation FD disclosure |
| Feb 12, 20248-K | Regulation FD disclosure |
| Feb 2, 20248-K | Results of operations |
| Jan 5, 20248-K | Results of operations |
2023 · 30 filings — 15 × 8-K, 5 × PX14A6G, 3 × 10-Q and 5 other forms
| Filed | What it is |
|---|---|
| Nov 6, 202310-Q | Quarterly report, Q3 2023 — revenue $13.93B (−6% y/y), net income $1.78B, EPS $1.00 |
| Aug 7, 202310-Q | Quarterly report, Q2 2023 — revenue $13.87B (−5% y/y), net income $2.02B, EPS $1.14 |
| May 5, 202310-Q | Quarterly report, Q1 2023 — revenue $12.22B (−10% y/y), net income $239.0M, EPS $0.13 |
| May 4, 2023PX14A6G | Shareholder exempt solicitation |
| Apr 20, 2023PX14A6G | Shareholder exempt solicitation |
| Apr 11, 2023PX14A6G | Shareholder exempt solicitation |
| Mar 28, 2023DEFA14A | Additional proxy materials |
| Mar 28, 2023PX14A6G | Shareholder exempt solicitation |
| Mar 28, 2023PX14A6G | Shareholder exempt solicitation |
| Mar 21, 2023ARS | Annual report to shareholders |
| Mar 21, 2023DEFA14A | Additional proxy materials |
| Mar 20, 2023DEFA14A | Additional proxy materials |
| Mar 20, 2023DEF 14A | Proxy statement |
| Mar 6, 2023PRE 14A | Preliminary proxy statement |
| Feb 17, 202310-K | Annual report, FY2022 — revenue $58.05B (+3% y/y), net income $11.84B, EPS $6.63 |
15 current reports (8-K) not listed; the year is on EDGAR.
2022 · 27 filings — 16 × 8-K, 4 × PX14A6G, 3 × 10-Q and 4 other forms
| Filed | What it is |
|---|---|
| Nov 4, 202210-Q | Quarterly report, Q3 2022 — revenue $14.81B (+3% y/y), net income $3.95B, EPS $2.21 |
| Aug 4, 202210-Q | Quarterly report, Q2 2022 — revenue $14.58B (+4% y/y), net income $924.0M, EPS $0.51 |
| May 6, 202210-Q | Quarterly report, Q1 2022 — revenue $13.54B (+4% y/y), net income $4.49B, EPS $2.51 |
| Apr 11, 2022PX14A6G | Shareholder exempt solicitation |
| Apr 4, 2022PX14A6G | Shareholder exempt solicitation |
| Mar 30, 2022PX14A6G | Shareholder exempt solicitation |
| Mar 25, 2022PX14A6G | Shareholder exempt solicitation |
| Mar 21, 2022DEFA14A | Additional proxy materials |
| Mar 21, 2022DEF 14A | Proxy statement |
| Mar 7, 2022PRE 14A | Preliminary proxy statement |
| Feb 18, 202210-K | Annual report, FY2021 — revenue $56.20B (+23% y/y), net income $11.54B, EPS $6.45 |
16 current reports (8-K) not listed; the year is on EDGAR.
2021 · 22 filings — 12 × 8-K, 3 × 10-Q, 3 × PX14A6G and 4 other forms
| Filed | What it is |
|---|---|
| Nov 2, 202110-Q | Quarterly report, Q3 2021 — revenue $14.34B (+11% y/y), net income $3.18B, EPS $1.78 |
| Aug 2, 202110-Q | Quarterly report, Q2 2021 — revenue $13.96B (+34% y/y), net income $766.0M, EPS $0.42 |
| May 7, 202110-Q | Quarterly report, Q1 2021 — revenue $13.01B (+51% y/y), net income $3.55B, EPS $1.99 |
| Apr 15, 2021PX14A6G | Shareholder exempt solicitation |
| Mar 31, 2021PX14A6G | Shareholder exempt solicitation |
| Mar 29, 2021PX14A6G | Shareholder exempt solicitation |
| Mar 22, 2021DEFA14A | Additional proxy materials |
| Mar 22, 2021DEF 14A | Proxy statement |
| Mar 8, 2021PRE 14A | Preliminary proxy statement |
| Feb 19, 202110-K | Annual report, FY2020 — revenue $45.80B (+38% y/y), net income $4.62B, EPS $2.72 |
12 current reports (8-K) not listed; the year is on EDGAR.
2020 · 32 filings — 21 × 8-K, 3 × 10-Q, 3 × PX14A6G and 5 other forms
| Filed | What it is |
|---|---|
| Nov 4, 202010-Q | Quarterly report, Q3 2020 — revenue $12.90B (+52% y/y), net income $2.31B, EPS $1.29 |
| Aug 4, 202010-Q | Quarterly report, Q2 2020 — revenue $10.43B (+26% y/y), net income −$738.0M, EPS −$0.46 |
| May 8, 202010-Q | Quarterly report, Q1 2020 — revenue $8.62B (+10% y/y), net income $3.01B, EPS $2.02 |
| May 1, 2020PX14A6G | Shareholder exempt solicitation |
| Apr 7, 2020PX14A6G | Shareholder exempt solicitation |
| Mar 26, 2020PX14A6G | Shareholder exempt solicitation |
| Mar 24, 2020DEFA14A | Additional proxy materials |
| Mar 23, 2020DEF 14A | Proxy statement |
| Mar 9, 2020PRE 14A | Preliminary proxy statement |
| Feb 21, 202010-K | Annual report, FY2019 — revenue $33.27B (+2% y/y), net income $7.88B, EPS $5.28 |
22 current reports (8-K) not listed; the year is on EDGAR.
2019 · 33 filings — 23 × 8-K, 3 × 10-Q, 3 × PX14A6G and 4 other forms
| Filed | What it is |
|---|---|
| Nov 6, 201910-Q | Quarterly report, Q3 2019 — revenue $8.48B (+3% y/y), net income $1.88B, EPS $1.26 |
| Aug 5, 201910-Q | Quarterly report, Q2 2019 — revenue $8.26B (−0% y/y), net income $741.0M, EPS $0.49 |
| May 3, 201910-Q | Quarterly report, Q1 2019 — revenue $7.83B (−1% y/y), net income $2.46B, EPS $1.65 |
| Apr 17, 2019PX14A6G | Shareholder exempt solicitation |
| Apr 1, 2019PX14A6G | Shareholder exempt solicitation |
| Mar 29, 2019PX14A6G | Shareholder exempt solicitation |
| Mar 22, 2019DEFA14A | Additional proxy materials |
| Mar 22, 2019DEF 14A | Proxy statement |
| Mar 8, 2019PRE 14A | Preliminary proxy statement |
| Feb 27, 201910-K | Annual report, FY2018 — revenue $32.75B (+16% y/y), net income $5.69B, EPS $3.66 |
23 current reports (8-K) not listed; the year is on EDGAR.
2018 · 20 filings — 11 × 8-K, 3 × 10-Q, 2 × PX14A6G and 4 other forms
| Filed | What it is |
|---|---|
| Nov 7, 201810-Q | Quarterly report, Q3 2018 — revenue $8.24B (+18% y/y), net income $2.75B, EPS $1.81 |
| Aug 7, 201810-Q | Quarterly report, Q2 2018 — revenue $8.28B (+19% y/y), net income $1.98B, EPS $1.26 |
| May 4, 201810-Q | Quarterly report, Q1 2018 — revenue $7.93B (+21% y/y), net income $2.78B, EPS $1.74 |
| Mar 27, 2018PX14A6G | Shareholder exempt solicitation |
| Mar 27, 2018PX14A6G | Shareholder exempt solicitation |
| Mar 19, 2018DEFA14A | Additional proxy materials |
| Mar 19, 2018DEF 14A | Proxy statement |
| Mar 7, 2018PRE 14A | Preliminary proxy statement |
| Feb 16, 201810-K | Annual report, FY2017 — revenue $28.22B (+10% y/y), net income $5.31B, EPS $3.30 |
11 current reports (8-K) not listed; the year is on EDGAR.
2017 · 12 filings — 6 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 7, 201710-Q | Quarterly report, Q3 2017 — revenue $7.00B (+9% y/y), net income $1.63B, EPS $1.01 |
| Aug 7, 201710-Q | Quarterly report, Q2 2017 — revenue $6.94B (+8% y/y), net income $1.92B, EPS $1.19 |
| May 5, 201710-Q | Quarterly report, Q1 2017 — revenue $6.54B (+10% y/y), net income $1.71B, EPS $1.06 |
| Mar 20, 2017DEF 14A | Proxy statement |
| Mar 8, 2017PRE 14A | Preliminary proxy statement |
| Feb 17, 201710-K | Annual report, FY2016 — revenue $25.64B (+12% y/y), net income $5.95B, EPS $3.63 |
6 current reports (8-K) not listed; the year is on EDGAR.
2016 · 20 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2015 · 22 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2014 · 22 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2013 · 13 filings — 5 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
Counted, not listed; the year is on EDGAR.
2012 · 1 filing — 1 × 8-K
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 59 filings — 42 × 4, 5 × 144, 4 × 424B5 and 6 other forms
| Filed | What it is |
|---|---|
| Oct 2, 20264 | Insider transaction (Form 4) |
| Oct 2, 20264 | Insider transaction (Form 4) |
| Aug 18, 20264 | Insider transaction (Form 4) |
| Aug 14, 2026144 | Notice of proposed sale (Form 144) |
| Aug 6, 2026424B5 | Prospectus supplement |
| Aug 5, 2026FWP | Free writing prospectus |
| Aug 4, 2026424B5 | Prospectus supplement |
| Jul 2, 20264 | Insider transaction (Form 4) |
| Jul 2, 20264 | Insider transaction (Form 4) |
| Jun 24, 202611-K | Employee plan annual report |
| Jun 1, 2026SD | Specialized disclosure (conflict minerals) |
| May 26, 2026144 | Notice of proposed sale (Form 144) |
| May 12, 20264 | Insider transaction (Form 4) |
| May 12, 20264 | Insider transaction (Form 4) |
| May 12, 20264 | Insider transaction (Form 4) |
| May 12, 20264 | Insider transaction (Form 4) |
| May 12, 20264 | Insider transaction (Form 4) |
| May 12, 20264 | Insider transaction (Form 4) |
| May 12, 20264 | Insider transaction (Form 4) |
| May 12, 20264 | Insider transaction (Form 4) |
| May 12, 20264 | Insider transaction (Form 4) |
| May 12, 20264 | Insider transaction (Form 4) |
| May 12, 20264 | Insider transaction (Form 4) |
| Apr 29, 2026SCHEDULE 13G | Other filings |
| Apr 2, 20264 | Insider transaction (Form 4) |
The newest 25 of 59 shown; the full year is on EDGAR.
2025 · 81 filings — 53 × 4, 15 × 144, 3 × 3 and 9 other forms
| Filed | What it is |
|---|---|
| Oct 2, 20254 | Insider transaction (Form 4) |
| Oct 2, 20254 | Insider transaction (Form 4) |
| Oct 2, 20254 | Insider transaction (Form 4) |
| Aug 22, 2025144 | Notice of proposed sale (Form 144) |
| Aug 21, 2025144 | Notice of proposed sale (Form 144) |
| Aug 14, 20254 | Insider transaction (Form 4) |
| Aug 12, 2025144 | Notice of proposed sale (Form 144) |
| Aug 8, 2025144 | Notice of proposed sale (Form 144) |
| Aug 7, 20254 | Insider transaction (Form 4) |
| Aug 5, 2025144 | Notice of proposed sale (Form 144) |
| Jul 30, 20253/A | Initial insider holdings (Form 3), amended |
| Jul 11, 20253 | Initial insider holdings (Form 3) |
| Jul 7, 2025SCHEDULE 13G/A | Other filings |
| Jul 2, 20254 | Insider transaction (Form 4) |
| Jul 2, 20254 | Insider transaction (Form 4) |
| Jul 2, 20254 | Insider transaction (Form 4) |
| Jun 13, 202511-K | Employee plan annual report |
| May 30, 2025SD | Specialized disclosure (conflict minerals) |
| May 13, 20254 | Insider transaction (Form 4) |
| May 13, 20254 | Insider transaction (Form 4) |
| May 13, 20254 | Insider transaction (Form 4) |
| May 13, 20254 | Insider transaction (Form 4) |
| May 13, 20254 | Insider transaction (Form 4) |
| May 13, 20254 | Insider transaction (Form 4) |
| May 13, 20254 | Insider transaction (Form 4) |
The newest 25 of 81 shown; the full year is on EDGAR.
2024 · 89 filings — 59 × 4, 16 × 144, 4 × S-8 and 7 other forms
| Filed | What it is |
|---|---|
| Dec 18, 20244 | Insider transaction (Form 4) |
| Dec 16, 2024144 | Notice of proposed sale (Form 144) |
| Nov 4, 2024S-8 | Employee stock plan registration |
| Nov 4, 2024S-8 | Employee stock plan registration |
| Oct 2, 20244 | Insider transaction (Form 4) |
| Oct 2, 20244 | Insider transaction (Form 4) |
| Oct 2, 20244 | Insider transaction (Form 4) |
| Oct 2, 20244 | Insider transaction (Form 4) |
| Sep 30, 20244 | Insider transaction (Form 4) |
| Aug 14, 2024S-8 | Employee stock plan registration |
| Aug 8, 2024144 | Notice of proposed sale (Form 144) |
| Aug 7, 20244 | Insider transaction (Form 4) |
| Aug 7, 2024144 | Notice of proposed sale (Form 144) |
| Aug 5, 2024144 | Notice of proposed sale (Form 144) |
| Jul 19, 20244 | Insider transaction (Form 4) |
| Jul 17, 2024144 | Notice of proposed sale (Form 144) |
| Jul 2, 20244 | Insider transaction (Form 4) |
| Jul 2, 20244 | Insider transaction (Form 4) |
| Jul 2, 20244 | Insider transaction (Form 4) |
| Jul 2, 20244 | Insider transaction (Form 4) |
| Jun 27, 202411-K | Employee plan annual report |
| Jun 3, 202425-NSE | Delisting notice from the exchange |
| May 31, 2024SD | Specialized disclosure (conflict minerals) |
| May 17, 202425-NSE | Delisting notice from the exchange |
| May 7, 20244 | Insider transaction (Form 4) |
The newest 25 of 89 shown; the full year is on EDGAR.
2023 · 73 filings — 55 × 4, 6 × 144, 5 × 3 and 6 other forms
Counted, not listed; the year is on EDGAR.
2022 · 72 filings — 58 × 4, 2 × 11-K, 2 × 3 and 7 other forms
Counted, not listed; the year is on EDGAR.
2021 · 80 filings — 68 × 4, 3 × SC 13G/A, 2 × 11-K and 5 other forms
Counted, not listed; the year is on EDGAR.
2020 · 96 filings — 71 × 4, 4 × 4/A, 3 × 3 and 13 other forms
Counted, not listed; the year is on EDGAR.
2019 · 83 filings — 68 × 4, 5 × SC 13G/A, 2 × 3 and 8 other forms
Counted, not listed; the year is on EDGAR.
2018 · 84 filings — 57 × 4, 9 × SC TO-I/A, 3 × 3 and 11 other forms
Counted, not listed; the year is on EDGAR.
2017 · 91 filings — 74 × 4, 6 × SC 13G/A, 4 × NO ACT and 5 other forms
Counted, not listed; the year is on EDGAR.
2016 · 78 filings — 57 × 4, 3 × SC 13G/A, 2 × 3 and 12 other forms
Counted, not listed; the year is on EDGAR.
2015 · 96 filings — 52 × 4, 14 × 425, 10 × SC TO-T/A and 15 other forms
Counted, not listed; the year is on EDGAR.
2014 · 98 filings — 50 × 4, 38 × 425, 4 × SC 13G and 5 other forms
Counted, not listed; the year is on EDGAR.
2013 · 60 filings — 54 × 4, 1 × 11-K, 1 × 424B3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2012 · 51 filings — 18 × 3, 10 × CORRESP, 8 × UPLOAD and 7 other forms
Counted, not listed; the year is on EDGAR.
About this data#
AbbVie Inc. (ABBV) has 1,514 filings on EDGAR going back to 2012: 15 annual reports, 41 quarterly reports and 202 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 20, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Oct 15, 2026, covered directors or officers; compensation. Over the last 13 months insiders sold $18.9M in 4 sales and bought nothing on the open market; 52 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been AbbVie Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read ABBV's latest 10-K?
- ABBV's latest annual report, a 10-K, was filed on Feb 20, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did ABBV last file an 8-K?
- On Oct 15, 2026 it covered directors or officers; compensation. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Oct 5, 2026.
- Are ABBV insiders buying or selling?
- Over the last 13 months insiders sold $18.9M in 4 sales and bought nothing on the open market; 52 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Donoghoe Nicholas (EVP, CHIEF BUS/STRAT OFFICER) sold 32,710 shares on Aug 14, 2026 for $8.2M. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has ABBV made?
- 1,514 filings are on EDGAR under the registrant records that have been AbbVie Inc., going back to 2012; 916 of them are insider ownership forms (Forms 3, 4, 5 and 144).